临床试验

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT：NCT06831136 · RECRUITING

NCT编号NCT06831136

状态RECRUITING

开始日期2025-03-26

完成时间2030-01-20

SponsorThe University of Texas Health Science Center, Houston (OTHER)

First posted2025-02-17

Last updated2026-10-08

简要摘要

The purpose of this study is to perform a pilot phase II trial to evaluate the safety and efficacy of combined EUS-RFA, chemotherapy, and systemic immunotherapy (pembrolizumab) for the treatment of locally advanced unresectable and metastatic Pancreatic ductal adenocarcinoma (mPDAC).

官方来源

在 ClinicalTrials.gov 上查看 →

数据来自 ClinicalTrials.gov API。有关最新状态，请参阅官方记录。